Gyrolab systems are supported by an increasing range of ready-to-use kits and these open platforms are also recognized for their ability to enable the rapid in-house development and evaluation of high performance immunoassays. To accelerate access to robust immunoassays to a higher level, we have prepared a number of protocols that have been rigorously tested to increase productivity while maintaining high quality requirements. New protocols will be added on a continuous basis.
As biologic drugs come off-patent and cheaper biosimilar versions become available it is vital to ensure that these versions have similar efficacy and safety profiles to their branded equivalents. The equivalence of biosimilars has been challenged because the tight relationship between structure and function of biologics means that pharmacology can be affected by even minor changes during the manufacturing process. We have therefore developed a number of robust Gyrolab assay protocols to support development of biosimilars and clinical PK studies. Using these protocols on Gyrolab systems will reduce time to market and increase productivity while maintaining quality requirements.
Would you like to submit a suggestion for a Gyrolab Assay? Your suggestion will be added to our new Gyrolab Assay development list